molecules of the month


selective RORgt inverse agonist

entered clinical dev. (psoriasis), discontinued

from HTS and SBDD

ACS Med. Chem. Lett., Apr. 10, 2020

Bristol Myers Squibb, Princeton, NJ

1 min read

BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development hit a wall in this space, and several publications of various company’s RORgt modulators have appeared in the last several months. Chemically, 251 is interesting with 5 stereocenters, none of which look particularly easy to set. Looking forward to the process paper on this one!

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: